Safety, pharmacokinetics, and pharmacodynamics of a next‐generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients
- 4 February 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 19 (4), 967-975
- https://doi.org/10.1111/jth.15259
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Inhibitor incidence in previously untreated patients with severe haemophilia B: a systematic literature reviewThrombosis and Haemostasis, 2016
- Prophylaxis in haemophilia B patients: unresolved issues and pharmacoeconomic implicationsHaemophilia, 2010
- Half-life extension through albumin fusion technologiesThrombosis Research, 2009
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaThe New England Journal of Medicine, 2007
- Reformulated BeneFix®: efficacy and safety in previously treated patients with moderately severe to severe haemophilia BHaemophilia, 2007
- Haemophilia B: Christmas diseaseExpert Opinion on Pharmacotherapy, 2005
- Prophylaxis for severe haemophilia: clinical and economical issuesHaemophilia, 2003
- The Hemophilias — From Royal Genes to Gene TherapyThe New England Journal of Medicine, 2001
- Haemophilia B mutations in Sweden: a population‐based study of mutational heterogeneityBritish Journal of Haematology, 2001
- Measurement of Activated Factor IX in Factor IX Concentrates: Correlation with In Vivo ThrombogenicityThrombosis and Haemostasis, 1995